Compare AbbVie Inc (ABBV) vs Amcor PLC (AMCR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Amcor PLC — how do they compare? AbbVie Inc trades at $254.02 (market cap $449.91B), while Amcor PLC trades at $44 (market cap $20.55B). The key difference: AbbVie Inc is far larger — about 21.9× Amcor PLC's market cap, and Amcor PLC pays the higher dividend (5.85%). Which is the better fit depends on your goals.
| ABBV | AMCR | |
|---|---|---|
Market Cap | $449.91B | $20.55B |
Sector | Health | Basic Materials |
52-Week High | $261.07 | $50.58 |
52-Week Low | $184.85 | $36.69 |
Enterprise Value | $513.38B | $35.67B |
Dividend Yield | 2.72% | 5.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.76, down 2.42% on the day, with strong technical momentum showing bullish moving averages despite overbought RSI readings. The company demonstrates solid fundamental performance with Q1 2026 earnings beating expectations at $2.65 EPS versus $2.59 expected, continuing a trend of quarterly beats. Revenue growth remains robust at $61.16 billion for 2025, supported by successful portfolio transition beyond Humira patent expiration.
AbbVie presents a compelling investment case with 68% analyst buy ratings and a $266.33 consensus target offering 4.5% upside. Key opportunities include Skyrizi and Rinvoq driving growth, while risks involve patent cliffs in the 2030s and high valuation multiples. The company's dividend aristocrat status and strong cash flow generation support continued shareholder returns.
AMCR trades at $44.45, down 1.22% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported revenue of $15.01B in 2025, with net income of $511M, and has beaten EPS estimates for the last three quarters. Recent news highlights sustainable packaging partnerships and leadership changes aimed at growth.
The stock offers a moderate upside to the consensus price target of $45.75, supported by a 69% analyst buy rating, but faces risks from integration challenges post-Berry acquisition and a high P/E ratio of 35.84. Earnings growth and synergy realization are key catalysts for 2027 recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Amcor PLC
Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.
Read more on AMCR →
